Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer

Weizer, Alon Z.; Tallman, Christopher; Montgomery, Jeffrey S.

doi:10.1007/s00345-010-0617-4

Cited by 25 publications

(22 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of these intravesical treatments is limited, and there is debate over both short-and long-term benefits in the recurrence rate in intermediaterisk tumors. [24][25][26] Tumors can also become refractory to treatment, and surgical removal of the bladder (cystectomy) is often needed when current intravesical treatment regimes have been exhausted.…”

Section: Discussionmentioning

confidence: 99%

“…28,29 Additionally, in culture, gemcitabine is selectively toxic to UCB cell lines, suggesting that this treatment might specifically target bladder tumor cells and spare their normal counterparts, reducing overall toxicity. [25][26][27]30,31 Several groups have evaluated the use of gemcitabine as an intravesical treatment for UCB. Bendary et al 31 concluded that gemcitabine had a better safety profile than BCG and was equally as effective in preventing the recurrence and progression of nonmuscle invasive bladder cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines

et al. 2013

View full text Add to dashboard Cite

MicroRNAs (miRNA) are small, noncoding RNAs with important regulatory roles in development, differentiation, cell proliferation, and death as well as the complex process of acquired drug resistance. The goal of this study was to identify specific miRNAs and their potential protein targets that confer acquired resistance to gemcitabine in urothelial carcinoma of the bladder (UCB) cell lines. Gemcitabine-resistant cells were established from 6 cell lines following exposure to escalating concentrations of the drug and by passaging cells in the presence of the drug over a 2-to 3-month period. Differential miRNA expression was identified in a microarray format comparing untreated controls with resistant cell lines, representing the maximum tolerated concentration, and results were validated via qRT-PCR. The involvement of specific miRNAs in chemoresistance was confirmed with transfection experiments, followed by clonogenic assays and Western blot analysis. Gemcitabine resistance was generated in 6 UCB cell lines. Microarray analysis comparing miRNA expression between gemcitabine-resistant and parental cells identified the differential expression of 66 miRNAs. Confirmation of differential expression was recorded via qRT-PCR in a subset of these miRNAs. Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells. Transfection of pre-miR-138 and pre-miR-1290 into parental cells attenuated cell death after exposure to gemcitabine, while transfection of pre-miR-let-7b and pre-miR-let-7i into the resistant cells augmented cell death. Mucin-4 was up-regulated in gemcitabine-resistant cells. Ectopic expression of let-7i and let-7b in the resistant cells resulted in the down-regulation of mucin-4. These results suggest a role for miRNAs 1290, 138, let-7i, and let-7b in imparting resistance to gemcitabine in UCB cell lines in part through the modulation of mucin-4. Alterations in these miRNAs and/or mucin-4 may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine in UCB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines

et al. 2013

View full text Add to dashboard Cite

show abstract

“…b In Tumorzellen kann sich das Virus jedoch erfolgreich vermehren, was zu einer Lyse der Zelle führt Abb. 2 8 Verschiedene Mechanismen einer Immunantwort nach Virotherapie war die Beobachtung, dass die Kombination von Viro-und Chemotherapie einen synergistischen Effekt aufwies und dabei keine erhöhte Toxizität zeigte [17].…”

Section: Die Virotherapieunclassified

“…Zum Zeitpunkt der Erstdiagnose werden etwa 75% der Blasenkarzinome als nicht-muskelinvasive Tumoren (NMIBC) diagnostiziert, die zwar durch eine geringe Progressionsrate, jedoch Rezidivraten nach 5 Jahren von 80% trotz Therapie charakterisiert sind. Durch die aktuell zugelassenen Therapieformen wird das Auftreten von Rezidiven innerhalb der ersten 5 Jahre nur um etwa 30% gesenkt, eine Verbesserung der tumorabhängigen Progressionswahrscheinlichkeit und damit verbundenen Mortalität konnte bislang jedoch nicht erzielt werden [2,3,4]. Die Gründe für den therapieresistenten Charakter der Tumoren sind außer-ordentlich vielfältig und basieren wahrscheinlich v. a. auf der genetischen Heterogenität dieser Tumorentität.…”

unclassified

YB-1-basierte Virotherapie

Holm

Retz

Gschwend

et al. 2015

Urologe

View full text Add to dashboard Cite

Therapeutic intervention using oncolytic viruses is called virotherapy. This type of virus is defined by the ability to replicate in tumor cells only and to destroy these cells upon replication. In addition, this virus type is able to induce a tumor-directed immune response. Early clinical trials have confirmed the safety profile of oncolytic viruses. Currently, different groups are working on the development of oncolytic viruses with a focus on treatment of nonmuscle invasive bladder cancer (NMIBC). A preliminary active recruiting clinical phase II/III trial ongoing in patients with a NMIBC was recently implemented in the United States. Our research group developed an oncolytic adenovirus that will soon enter a clinical phase I trial in patients diagnosed with glioma. This virus is being further modified for the treatment of NMIBC. In this review article, recent developments in the design and use of virotherapy in bladder cancer are summarized.

show abstract

“…Response rates are as high as 70% in patients with carcinoma in situ alone. 21 Shelley et al 22 performed a meta-analysis of 6 randomized controlled studies including 585 patients with Ta and T1 disease undergoing TURBT with or without subsequent BCG. This study showed a 70% lower likelihood of recurrence at 1 year in patients receiving BCG.…”

Section: Use Of Bacillus Calmette-guérin In Nmibcmentioning

confidence: 99%

Quality Indicators in the Management of Bladder Cancer

Montgomery¹,

Miller²,

Weizer³

2013

J Natl Compr Canc Netw

Self Cite

View full text Add to dashboard Cite

Bladder cancer is predominantly seen in elderly patients. With the aging United States population, the incidence and prevalence of bladder cancer are on the rise, heightening the relevance of this disease as a public health issue. Despite having one of the greatest average cancer treatment costs per patient, improvements in disease-specific survival have been subtle. Clinical guidelines based predominantly on expert opinion and randomized controlled studies offer some guidance, but adherence to these guidelines is lacking. Building awareness of quality indicators to optimize patient care represents an opportunity to improve bladder cancer outcomes. Although quality indicators exist for other disease states, widely accepted quality indicators for the management of bladder cancer have not yet been established. This article proposes an initial set of quality indicators for both non-muscle-invasive and muscle-invasive bladder cancer based on established clinical guidelines and the available literature. (JNCCN 2013;11:492-500) NCCN: Continuing Education Accreditation StatementThis activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial support was received for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.This activity is approved for 1.0 contact hour. Approval as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at http://education.nccn.org/ node/17316; and 4) view/print certificate.Release date: April 11, 2013; Expiration date: April 11, 2014. Learning ObjectivesUpon completion of this activity, participants will be able to:• Identify proposed quality indicators for non-muscleinvasive and muscle-invasive bladder cancer.• Discuss treatment recommendations and guidelines for non-muscle-invasive and muscle-invasive bladder cancer. Ms. Harrold has disclosed that she has no relevant financial relationships. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information OperationsMs. Grego...

show abstract

Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer

Cited by 25 publications

References 82 publications

MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines

MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines

YB-1-basierte Virotherapie

Quality Indicators in the Management of Bladder Cancer

Contact Info

Product

Resources

About